BCMA CAR T Cell Binding Strength Optimization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for B cell-related conditions, such as multiple myeloma, using chimeric antigen receptors (CARs) directed against BCMA, face challenges including unpredictable therapeutic efficacy and the risk of cytokine storms due to variable antigen binding domain strength.
Innovation Solution
A method involving the administration of immune cells expressing BCMA CARs, followed by monitoring soluble BCMA levels in tissue samples. If the second-level soluble BCMA exceeds 30% of the initial level, a non-CAR T cell therapy is subsequently provided to treat the disease.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If the antigen binding domain binds too strongly, then the CAR T cells can effectively target and clear cancer cells, but the CAR T cells induce massive cytokine release resulting in a potentially fatal immune reaction
Solution Approach 1:
The patent applies parameter changes by systematically varying the antigen binding domain strength through different antibody variants (e.g., wild-type vs. mutated antibodies like 4D10, 6F11, 1F5). By modifying amino acid sequences and measuring binding affinities (KD values), the invention identifies optimal binding strengths that achieve therapeutic efficacy without triggering cytokine storms. This is evident in the comparison of different CAR constructs with varying antigen binding characteristics.
Solution Approach 2:
The patent employs feedback mechanisms by measuring cytokine release (e.g., IL-6 levels) and therapeutic response in preclinical models to evaluate CAR T cell performance. The data from these measurements feed back into the selection process, allowing researchers to identify which antigen binding domains achieve the right balance between efficacy and safety. The patent uses this feedback to select specific antibody variants for further development.
2Object-affected harmful factors
If the antigen binding domain binds too weakly, then the risk of cytokine storms is reduced, but the CAR T cells do not display sufficient therapeutic efficacy in clearing cancer cells
Solution Approach 1:
The patent systematically adjusts the binding affinity parameter by testing multiple antibody variants with different strengths. Through controlled modification of amino acid sequences and measurement of binding characteristics, the invention identifies the optimal range of binding strength that provides sufficient therapeutic efficacy while avoiding excessive cytokine release. This parameter optimization is central to resolving the contradiction between weak binding (safe but ineffective) and strong binding (effective but dangerous).
3Reliability
If traditional chemotherapy and radiotherapy are used to treat B cell malignancies, then some cancer cells can be killed, but toxic side effects limit the utility of these treatments
Solution Approach 1:
The patent uses CAR T cells as an intermediary between the immune system and cancer cells. Instead of directly administering toxic chemicals or radiation, the invention creates genetically modified T cells that express chimeric antigen receptors specific to B cell malignancies. These CAR T cells serve as living mediators that selectively target and kill cancer cells through immune-mediated mechanisms, avoiding the non-specific toxicity of traditional chemotherapy and radiotherapy.
4Reliability
If immunotherapy with therapeutic antibodies is used to treat B cell malignancies, then some cancer cells can be targeted, but poor pharmacokinetic profiles and rapid elimination by serum proteases limit success
Solution Approach 1:
The patent transitions from using passive antibody intermediaries to using living CAR T cell intermediaries. Therapeutic antibodies are rapidly cleared by serum proteases and have poor pharmacokinetic profiles, but genetically modified T cells expressing antigen-specific receptors can persist in the body for extended periods, continuously surveilling and eliminating cancer cells. This living intermediary approach overcomes the limitations of protein-based therapeutics.
Solution Approach 2:
The CAR T cells are engineered to be self-sustaining and self-replicating within the patient's body. Once administered, these cells can proliferate and maintain themselves without requiring continuous external administration of therapeutic antibodies. The cells express their own antigen recognition machinery and can autonomously target and kill cancer cells, providing sustained therapeutic action without being subject to the rapid clearance that plagues circulating antibodies.
Data Source
AI summary
Provided herein are uses of anti-B cell maturation antigen (BCMA) chimeric antigen receptors (CARs) for treating B-cell related conditions, such as BCMA-expressing cancers.